30-Day FRN

Federal Register / Vol. 87, No. 190 / Monday, October 3, 2022 / Notices
benefits to certain survivors of
individuals who die as a direct result of
the administration or use of the Covered
Countermeasures. The causal
connection between the countermeasure
and the serious physical injury must be
supported by compelling, reliable, valid,
medical and scientific evidence in order
for the individual to be considered for
compensation. The CICP is
administered by the Health Resources
and Services Administration, within the
Department of Health and Human
Services. Information about the CICP is
available at 855–266–2427 (toll-free) or
http://www.hrsa.gov/cicp/.
XV. Amendments
42 U.S.C. 247d–6d(b)(4)
The October 10, 2008 declaration
under the PREP Act for smallpox
countermeasures was first published on
October 17, 2008 and amended and
republished on January 1, 2016. This is
the second amendment to and
republication of the declaration.
Any further amendments to this
declaration will be published in the
Federal Register.
(Authority: 42 U.S.C. 247d–6d)
Xavier Becerra,
Secretary.
[FR Doc. 2022–21412 Filed 9–30–22; 8:45 am]
BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Advisory Council on Alzheimer’s
Research, Care, and Services; Meeting
Assistant Secretary for
Planning and Evaluation, HHS.
ACTION: Notice of meeting.
AGENCY:

This notice announces the
public meeting of the Advisory Council
on Alzheimer’s Research, Care, and
Services (Advisory Council). The
Advisory Council provides advice on
how to prevent or reduce the burden of
Alzheimer’s disease and related
dementias (ADRD) on people with the
disease and their caregivers. During the
October 24, 2022 meeting the Advisory
Council will hear presentations on
access to long-term services and
supports as well as end-of-life
challenges for people living with ADRD.
Federal agencies will provide updates
including a presentation from the
Administration for Community Living
on the new National Strategy to Support
Family Caregivers.
DATES: The meeting will be held on
October 24, 2022 from 9:00 a.m. to 4:30
p.m. EST.

lotter on DSK11XQN23PROD with NOTICES1

SUMMARY:

VerDate Sep<11>2014

19:00 Sep 30, 2022

Jkt 259001

The meeting will be a
hybrid of in-person and virtual. The
meeting will be held in Room 800 of the
Hubert H. Humphrey Building, 200
Independence Avenue SW, Washington,
DC 20201. It will also stream live at
www.hhs.gov/live.
Comments: Time is allocated on the
agenda to hear public comments from
4:00 p.m. to 4:30 p.m. The time for oral
comments will be limited to two (2)
minutes per individual. In order to
provide a public comment, please
register by emailing your name to
[email protected] by Thursday, October 20.
Registered commenters may provide
their comments either in-person or
virtually on Friday, October 21.
Registered commenters attending
virtually will receive both a dial-in
number and a link to join the meeting
virtually; individuals will have the
choice to either join virtually via the
link, or to call in only by using the dialin number. Note: There may be a 30–45
second delay in the livestream video
presentation of the conference. For this
reason, if you have pre-registered to
submit a public comment, it is
important to connect to the meeting by
3:45 p.m. to ensure that you do not miss
your name and allotted time when
called. If you miss your name and
allotted time to speak, you may not be
able to make your public comment. All
participant audio lines will be muted for
the duration of the meeting and only
unmuted by the Host at the time of the
participant’s public comment. Should
you have questions during the session
email [email protected] and someone will
respond to your message as quickly as
possible.
In order to ensure accuracy, please
submit a written copy of oral comments
for the record by emailing napa@
hhs.gov by Tuesday, October 25. These
comments will be shared on the website
and reflected in the meeting minutes.
In lieu of oral comments, formal
written comments may be submitted for
the record by Tuesday, October 25 to
Helen Lamont, Ph.D., OASPE, 200
Independence Avenue SW, Room 424E,
Washington, DC 20201. Comments may
also be sent to [email protected]. Those
submitting written comments should
identify themselves and any relevant
organizational affiliations.
FOR FURTHER INFORMATION CONTACT:
Helen Lamont, 202–260–6075,
[email protected]. Note: The
meeting will be available to the public
live at www.hhs.gov/live
SUPPLEMENTARY INFORMATION: Notice of
these meetings is given under the
Federal Advisory Committee Act (5
U.S.C. app. 2, section 10(a)(1) and
ADDRESSES:

PO 00000

Frm 00036

Fmt 4703

Sfmt 4703

59805

(a)(2)). Topics of the Meeting:
Aducanumab, dementia risk reduction,
recommendations.
Procedure and Agenda: The meeting
will be webcast at www.hhs.gov/live and
video recordings will be added to the
National Alzheimer’s Project Act
website when available, after the
meeting.
Authority: 42 U.S.C. 11225; Section
2(e)(3) of the National Alzheimer’s
Project Act. The panel is governed by
provisions of Public Law 92–463, as
amended (5 U.S.C. appendix 2), which
sets forth standards for the formation
and use of advisory committees.
Dated: September 28, 2022.
Benjamin Sommers,
Senior Official Performing the Duties of the
Assistant Secretary for Planning and
Evaluation, Deputy Assistant Secretary for
Health Policy.
[FR Doc. 2022–21396 Filed 9–30–22; 8:45 am]
BILLING CODE 4150–05–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OS–0990–new]

Agency Information Collection
Request. 30-Day Public Comment
Request
Office of the Secretary, HHS.
Notice.

AGENCY:
ACTION:

In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before November 2, 2022.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT:
Sherrette Funn, [email protected]
or (202) 264–0041. When submitting
comments or requesting information,
please include the document identifier
0990–New–30D and project title for
reference.
SUPPLEMENTARY INFORMATION: Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
SUMMARY:

E:\FR\FM\03OCN1.SGM

03OCN1

59806

Federal Register / Vol. 87, No. 190 / Monday, October 3, 2022 / Notices

following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Teen
Pregnancy Prevention Fiscal Year 2020/
2021 Tier 1 and Tier 2 Implementation
Study.
Type of Collection: New.
OMB No. 0990–NEW-Office of
Population Affairs.

Abstract: The Office of Population
Affairs (OPA), U.S. Department of
Health and Human Services (HHS) is
requesting 2 years of approval by OMB
on a new collection. The Teen
Pregnancy Prevention (TPP) Tier 1 and
Tier 2 Implementation Study will
document how 75 grantees funded in
2020 and 2021 are implementing their
grant strategies to reduce rates of teen
pregnancy and sexually transmitted
infections in their selected communities
or priority areas. OPA anticipates that
grantees will employ diverse strategies
working with partner organizations
within communities to implement their
teen pregnancy prevention projects. To
document approaches and experiences

of each grantee, a lead staff member in
each grantee organization and up to one
other staff member will be interviewed
during an in-person or virtual site visit.
Up to two staff members from key
grantee partner organizations will be
interviewed for 31 of the 62 Tier 1
grantees and all 13 Tier 2 grantees.
Interview participants will include up
to 124 Tier 1 grantee staff members, 62
Tier 1 grantee partner organization staff
members, 26 Tier 2 grantee staff
members and 26 Tier 2 grantee partner
organization staff members. The data
collection effort will occur once and
will primarily affect public and private
businesses.

ESTIMATED ANNUALIZED BURDEN TABLE

Tier
Tier
Tier
Tier

1
1
2
2

grantee
grantee
grantee
grantee

Total burden
hours

director and other staff .............................................................
partner staff ..............................................................................
director and other staff .............................................................
partner staff ..............................................................................

124
62
26
26

1
1
1
1

2
1
2
1

248
62
52
26

Total ..........................................................................................................

238

........................

........................

388

Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2022–21368 Filed 9–30–22; 8:45 am]
BILLING CODE 4150–30–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings

lotter on DSK11XQN23PROD with NOTICES1

Average
burden per
response
(in hours)

Number
responses per
respondent

Number of
respondents

Type of respondent

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group
Lifestyle and Health Behaviors Study
Section.
Date: October 27–28, 2022.

VerDate Sep<11>2014

19:00 Sep 30, 2022

Jkt 259001

Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency, Bethesda, 1 Bethesda
Metro Center, Bethesda, MD 20814.
Contact Person: Lisa T Wigfall, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007G,
Bethesda, MD 20892, (301) 594–5622,
[email protected].
Name of Committee: Applied Immunology
and Disease Control Integrated Review Group
Vaccines Against Microbial Diseases Study
Section.
Date: October 27–28, 2022.
Time: 9 a.m. to 8 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Hilton Garden Inn Washington
DC/Georgetown, 2201 M Street NW,
Washington, DC 20037.
Contact Person: Jian Wang, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4218,
MSC 7812, Bethesda, MD 20892, (301) 435–
2778, [email protected].
Name of Committee: Digestive, Kidney and
Urological Systems Integrated Review Group
Digestive System Host Defense, Microbial
Interactions and Immune and Inflammatory
Disease Study Section.
Date: October 27–28, 2022.
Time: 9 a.m. to 8 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).

PO 00000

Frm 00037

Fmt 4703

Sfmt 4703

Contact Person: Aiping Zhao, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2188,
Bethesda, MD 20892–7818, (301) 435–0682,
[email protected].
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group Respiratory Integrative Biology and
Translational Research Study Section.
Date: October 27–28, 2022.
Time: 9 a.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bradley Nuss, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC7814, Bethesda, MD 20892, (301) 451–
8754, [email protected].
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group Imaging
Technology Development Study Section.
Date: October 27–28, 2022.
Time: 9 a.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Guo Feng Xu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5122,
MSC 7854, Bethesda, MD 20892, (301) 237–
9870, [email protected].

E:\FR\FM\03OCN1.SGM

03OCN1